SEC subpoenaes BioMarin in drisapersen probe; Job hunting? The FDA has hundreds of open positions
BioMarin $BMRN has more headaches to contend with on its Duchenne muscular dystrophy drug drisapersen. The company says in its newly posted quarterly report with the SEC that it is cooperating with an SEC investigation into the drug, which was rejected by the FDA and the EMA. BioMarin has been rethinking its decision to bury the drug, pondering an appeal of the FDA’s position. Its statement on the SEC: In August 2016, we received a subpoena from the staff of the SEC requesting that we produce documents in connection with a non-public, fact-finding inquiry related to our former drisapersen program. The letter enclosing the subpoena states that the investigation and the subpoena do not mean that the Company or anyone else has broken the law, or that the SEC has a negative opinion of any person, entity or security. We intend to cooperate fully with the SEC in this matter. We are not able to predict whether any proceeding may be instituted in connection with the subpoena, or the outcome of any proceeding that may be instituted.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.